Related Experiment Video

Updated: Jan 18, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.4K

Estimating the Effects of Continuous Albuterol Dosage on Clinical Outcomes for Pediatric Critical Asthma

Daniel P Riggins1,2, Eneida A Mendonca3,4, Lucas Bulgarelli3

  • 1Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.

Pediatric Pulmonology
|September 11, 2025
PubMed

Insights

A reduced initial dose of continuous albuterol (10 mg/h) is as effective as the standard dose (15 mg/h) for pediatric asthma exacerbations. This lower dose also significantly shortens treatment duration, potentially optimizing care.

Area of Science:

  • Pediatric Emergency Medicine
  • Respiratory Medicine
  • Clinical Pharmacology

Background:

  • Continuous albuterol is crucial for severe pediatric asthma exacerbations.
  • Current pediatric dosing often relies on adult guidelines, lacking specific evidence.
  • This study addresses the need for evidence-based dosing in critically ill children.

Purpose of the Study:

  • To compare clinical outcomes of reduced (10 mg/h) vs. standard (15 mg/h) continuous albuterol doses.
  • To evaluate the efficacy and safety of lower-dose continuous albuterol in pediatric asthma.
  • To inform optimal dosing strategies for severe pediatric asthma exacerbations.

Main Methods:

  • Retrospective cohort study of pediatric patients (ages 2-18) with critical asthma exacerbations (2014-2022).
  • Stabilized inverse probability weighting (SIPW) used for confounding factor adjustment.
  • Primary outcome: change in Pediatric Asthma Severity Score (PASS) at 24h; secondary: albuterol duration, PICU/hospital length of stay.

Main Results:

  • No significant difference in PASS change at 24h between 10 mg/h and 15 mg/h groups (p=0.207).
  • Similar PICU and hospital lengths of stay for both dosing groups.
  • The 10 mg/h group demonstrated a significantly shorter duration of continuous albuterol therapy (p<0.001).

Conclusions:

  • Starting continuous albuterol at 10 mg/h yields comparable clinical outcomes to 15 mg/h in pediatric critical asthma.
  • A lower initial dose may lead to optimized resource utilization.
  • Reduced dosing could potentially minimize treatment-related adverse effects in pediatric patients.
Abstract

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.4K
Conducting Respiratory Oscillometry in an Outpatient Setting14:49

Conducting Respiratory Oscillometry in an Outpatient Setting

Published on: April 8, 2022

8.4K

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
741
Antiasthma Drugs: &#946;2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
756
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
257
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214